Skip Navigation


NDT Advance Access originally published online on July 14, 2008
Nephrology Dialysis Transplantation 2008 23(10):3050-3052; doi:10.1093/ndt/gfn393
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/10/3050    most recent
gfn393v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Floege, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Floege, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: should we CARE-2 avoid them?

Jürgen Floege

Division of Nephrology and Immunology, Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany

Jürgen Floege, Division of Nephrology, University Hospital, RWTH Aachen, Pauwelsstr 30, 52074 Aachen, Germany. Tel: +49-241-8089-530; Fax: +49-241-8082-446; E-mail: juergen.floege@rwth-aachen.de

Keywords: calcification; calcium acetate; dialysis; phosphate binder; sevelamer

The first 10% of the full text of this article appears below.

Excess cardiovascular mortality is well documented in dialysis patients. Vascular calcifications, no matter where and how they are detected, are a potent predictor of mortality in such patients [1]. Many, albeit not all, studies have documented that an elevated serum calcium-phosphate product as well as the total dose of calcium-containing phosphate binders ingested correlates with the extent of vascular calcifications [2,3]. Thus, oral calcium loading might contribute to vascular calcification. This would be of particular importance in patients with serum parathyroid hormone levels <100 pg/ml, which usually indicates low-turnover bone disease [3], where the capacity of the bone to buffer calcium challenges is limited. Further evidence for a detrimental role of calcium loading is derived from the observation that the magnitude of intradialytic serum calcium increases predicts . . . [Full Text of this Article]



   Treat-to-goal study (TTG) [5]
 


   Renagel in new dialysis (RIND) patients’ study [6]
 


   Calcium acetate renagel evaluation (CARE-2) study [7]
 
A closer look at TTG versus CARE-2


   Conclusion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
J. Rottembourg
Calcium-containing phosphate binders: should we CARE-2 avoid them?
Nephrol. Dial. Transplant., August 1, 2009; 24(8): 2610 - 2610.
[Full Text] [PDF]